Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Biotechnology

Healthcare
$1.61 -0.87%

-$0.02 today

Market cap
$80.25M
Beta
0.00
P/E (TTM)
-16.7
EPS (TTM)
-$0.14
52W Low $2.01High $48.91

Volume 0.02M

Average 0.34M

PLYX Common Stock Issued

Cash raised by issuing new shares.

Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX

Common Stock Issued · Q4 FY2025 · quarter ended Dec 2025

Common stock issued declines year over year

Q4 FY2025 common stock issued of $888K fell 67.7% year over year. Sequentially, it fell 74.5% from the prior quarter.

Context

  • Common stock issued increased in 1 of the last 2 fiscal years.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
$888K-74.5% QoQ
Last fiscal yearDec 2025
$4.47M-39.0% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-67.7%——
1 year-39.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
4.47M USD
Year-over-year change
-39.0%

Common Stock Issued vs competitors

How PLYX compares with its peers on the latest reported figures

  • PLYX's FY2025 common stock issued of $4.47M is the smallest of the 8 companies compared; the peer median is $50.88M.
  • Its year-over-year change of -39.0% is the 5th highest of 6, against a peer median of +33293.9%.
PLYX Competitors Peer median
Common Stock Issued for PLYX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JBIOJade Biosciences, Inc.LTM Mar 2026$360.66M —+869.3%—
CBIOCrescent Biopharma, Inc.LTM Mar 2026$170.67M +54062.1%-89.4%1436.2%
LYELLyell Immunopharma, Inc.LTM Mar 2026$102.13M +7762.1%+65.6%329448.4%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$50.88M -51.5%-16.6%180.3%
KLRSKalaris Therapeutics IncLTM Mar 2026$50.07M ———
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$37.38M +42373.9%-88.3%—
PTHSPelthos Therapeutics Inc.LTM Mar 2026$27.59M +33293.9%—99.6%
PLYXPolaryx Therapeutics, Inc. Common StockFY2025$4.47M -39.0%——
Peer median (excluding PLYX) $50.88M+33293.9%-16.6%808.3%

Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Intrinsic Alpha fair value

Locked

Current Price

$1.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.